10:36 AM
 | 
Jan 11, 2018
 |  BC Innovations  |  Emerging Company Profile

Next, after T cells

NextCure is exploiting myeloid targets to enhance other immunotherapies

Editor's Note: This article was updated on Jan 12, 2018 at 10:22 AM PST

PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T cell-targeted compounds and extend their uses to non-responders or patients who develop resistance.

The company raised $67 million in series A funding in 2016, and expects to submit an IND on its first candidate in the third quarter and start a Phase I trial by year-end.

Chen, a professor of immunobiology at Yale University, helped discover PD-1 and other immune checkpoint targets. He previously founded immune checkpoint company Amplimmune Inc., which was acquired by AstraZeneca plc in 2013.

His latest venture uses the FIND-IO discovery...

Read the full 585 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >